| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on January 9, 2007
Accepted on February 1, 2007
Baylor College of Medicine, Department of Cell Biology, 1 Baylor Plaza, Houston, TX 77030-3498
* To whom correspondence should be addressed. E-mail: berto{at}bcm.tmc.edu.
It is now over a decade since the first nuclear receptor coactivator, SRC-1, was cloned and discovered to be a new type of transcription factor that does not bind DNA, but rather, binds directly or indirectly to nuclear receptors (NRs) to mediate their transcriptional potency. The NR coactivators belong to a class of molecules now termed ‘coregulators’. Employing an ‘operational’ definition, we define coactivators as molecules which enhance transcription, and corepressors as molecules which repress transcription. Current evidence indicates that this operational definition can be modified by gene, cell and signaling context for any one coregulator. Our current understanding is that NRs and other DNA-binding transcription factors (TFs) search out the target genes to be regulated by binding to specific DNA sequences (or other TFs at such sequences) termed TF-response elements (1); the second job of NRs is to recruit the coregulators that perform all of the subsequent reactions needed to induce or repress expression of genes. Initially, we believed that coactivators were simply ‘adapters’ that stabilized the general transcription machinery at the TATA box. This explanation proved to be incorrect. Over the past decade, the mechanistic importance of coregulators has expanded logarithmically, and we now realize that they perform virtually ‘all’ of the reactions needed for control of enhancer dependent gene expression.
NURSA Molecule Pages Link:
This article has been cited by other articles:
 |
|
 |
|
  H.-J. van den Ham and R. J. de Boer From the two-dimensional Th1 and Th2 phenotypes to high-dimensional models for gene regulation Int. Immunol., September 2, 2008; (2008) dxn093v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Dimple, S. S. Nair, R. Rajhans, P. R. Pitcheswara, J. Liu, S. Balasenthil, X.-F. Le, M. E. Burow, N. Auersperg, R. R. Tekmal, et al. Role of PELP1/MNAR Signaling in Ovarian Tumorigenesis Cancer Res., June 15, 2008; 68(12): 4902 - 4909. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. K. Nagpal, S. Nair, D. Chakravarty, R. Rajhans, S. Pothana, D. W. Brann, R. R. Tekmal, and R. K. Vadlamudi Growth Factor Regulation of Estrogen Receptor Coregulator PELP1 Functions via Protein Kinase A Pathway Mol. Cancer Res., May 1, 2008; 6(5): 851 - 861. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Biserni, F. Giannessi, A. F. Sciarroni, F. M. Milazzo, A. Maggi, and P. Ciana In Vivo Imaging Reveals Selective Peroxisome Proliferator Activated Receptor Modulator Activity of the Synthetic Ligand 3-(1-(4-Chlorobenzyl)-3-t-butylthio-5-isopropylindol-2-yl)-2,2-dimethylpropanoic acid (MK-886) Mol. Pharmacol., May 1, 2008; 73(5): 1434 - 1443. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Li, M.-J. Chu, and J. Xu Tissue- and Nuclear Receptor-Specific Function of the C-Terminal LXXLL Motif of Coactivator NCoA6/AIB3 in Mice Mol. Cell. Biol., December 1, 2007; 27(23): 8073 - 8086. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Stygar, B. Masironi, H. Eriksson, and L. Sahlin Studies on estrogen receptor (ER) {alpha} and {beta} responses on gene regulation in peripheral blood leukocytes in vivo using selective ER agonists J. Endocrinol., July 1, 2007; 194(1): 101 - 119. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
